Search

Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined. The objective of this study was to evaluate the efficacy and safety of intradermal injections with 0.5% minoxidil for the management of female androgenetic alopecia in a randomized, placebo‐controlled trial. A total of 54 women diagnosed with female androgenetic alopecia were divided into two groups: one group received intradermal injections of 0.5% minoxidil, and the other received 0.9% saline. Biopsy, trichogram, Trichoscan (Tricholog GmbH, Freiburg, Germany), and self‐assessment findings were used to evaluate the outcomes of treatment with minoxidil. In the treated group, there was a significant increase in the terminal‐to‐vellus hair ratio (P <.001) and in the percentage of anagen hairs (P =.048) and an improvement in hair loss and volume (P =.021 and P =.028, respectively). These results show that intradermal injections with minoxidil were more effective than placebo (P <.001) in the treatment of female androgenetic alopecia with a good safety profile. [ABSTRACT FROM AUTHOR]